vs
Revvity（RVTY）与TRINET GROUP, INC.（TNET）财务数据对比。点击上方公司名可切换其他公司
TRINET GROUP, INC.的季度营收约是Revvity的1.6倍（$1.2B vs $772.1M），Revvity同比增速更快（5.9% vs -2.2%），Revvity自由现金流更多（$161.8M vs $43.0M），过去两年Revvity的营收复合增速更高（9.0% vs -0.6%）
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
TriNet Group, Inc.是一家面向中小企业的专业雇主组织，总部位于加州都柏林，服务员工规模在3至2500人之间的各类机构。可提供薪资管理、健康福利管理服务，还能为客户提供劳动法规合规、风险降低相关咨询，可作为外包人力资源部门为企业分担人事相关事务。
RVTY vs TNET — 直观对比
营收规模更大
TNET
是对方的1.6倍
$772.1M
营收增速更快
RVTY
高出8.0%
-2.2%
自由现金流更多
RVTY
多$118.8M
$43.0M
两年增速更快
RVTY
近两年复合增速
-0.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $772.1M | $1.2B |
| 净利润 | $98.4M | — |
| 毛利率 | — | — |
| 营业利润率 | 14.5% | 0.1% |
| 净利率 | 12.7% | — |
| 营收同比 | 5.9% | -2.2% |
| 净利润同比 | 3.9% | — |
| 每股收益（稀释后） | $0.86 | $0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RVTYTNET
| Q4 25 | $772.1M | $1.2B | ||
| Q3 25 | $698.9M | $1.2B | ||
| Q2 25 | $720.3M | $1.2B | ||
| Q1 25 | $664.8M | $1.3B | ||
| Q4 24 | $729.4M | $1.3B | ||
| Q3 24 | $684.0M | $1.2B | ||
| Q2 24 | $691.7M | $1.2B | ||
| Q1 24 | $649.9M | $1.3B |
净利润RVTYTNET
| Q4 25 | $98.4M | — | ||
| Q3 25 | $46.7M | $34.0M | ||
| Q2 25 | $53.9M | $37.0M | ||
| Q1 25 | $42.2M | $85.0M | ||
| Q4 24 | $94.6M | — | ||
| Q3 24 | $94.4M | $45.0M | ||
| Q2 24 | $55.4M | $60.0M | ||
| Q1 24 | $26.0M | $91.0M |
毛利率RVTYTNET
| Q4 25 | — | — | ||
| Q3 25 | 53.6% | — | ||
| Q2 25 | 54.5% | — | ||
| Q1 25 | 56.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 56.3% | — | ||
| Q2 24 | 55.7% | — | ||
| Q1 24 | 54.6% | — |
营业利润率RVTYTNET
| Q4 25 | 14.5% | 0.1% | ||
| Q3 25 | 11.7% | 4.1% | ||
| Q2 25 | 12.6% | 4.1% | ||
| Q1 25 | 10.9% | 8.9% | ||
| Q4 24 | 16.3% | -2.9% | ||
| Q3 24 | 14.3% | 4.7% | ||
| Q2 24 | 12.4% | 6.5% | ||
| Q1 24 | 6.8% | 9.7% |
净利率RVTYTNET
| Q4 25 | 12.7% | — | ||
| Q3 25 | 6.7% | 2.8% | ||
| Q2 25 | 7.5% | 3.0% | ||
| Q1 25 | 6.4% | 6.6% | ||
| Q4 24 | 13.0% | — | ||
| Q3 24 | 13.8% | 3.6% | ||
| Q2 24 | 8.0% | 4.9% | ||
| Q1 24 | 4.0% | 7.2% |
每股收益（稀释后）RVTYTNET
| Q4 25 | $0.86 | $0.02 | ||
| Q3 25 | $0.40 | $0.70 | ||
| Q2 25 | $0.46 | $0.77 | ||
| Q1 25 | $0.35 | $1.71 | ||
| Q4 24 | $0.77 | $-0.44 | ||
| Q3 24 | $0.77 | $0.89 | ||
| Q2 24 | $0.45 | $1.20 | ||
| Q1 24 | $0.21 | $1.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $919.9M | $287.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $7.3B | $54.0M |
| 总资产 | $12.2B | $3.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资RVTYTNET
| Q4 25 | $919.9M | $287.0M | ||
| Q3 25 | $931.4M | $321.0M | ||
| Q2 25 | $991.8M | $407.0M | ||
| Q1 25 | $1.1B | $349.0M | ||
| Q4 24 | $1.2B | $360.0M | ||
| Q3 24 | $1.2B | $301.0M | ||
| Q2 24 | $2.0B | $249.0M | ||
| Q1 24 | $1.7B | $383.0M |
股东权益RVTYTNET
| Q4 25 | $7.3B | $54.0M | ||
| Q3 25 | $7.4B | $110.0M | ||
| Q2 25 | $7.6B | $107.0M | ||
| Q1 25 | $7.6B | $63.0M | ||
| Q4 24 | $7.7B | $69.0M | ||
| Q3 24 | $7.9B | $129.0M | ||
| Q2 24 | $7.9B | $100.0M | ||
| Q1 24 | $7.8B | $143.0M |
总资产RVTYTNET
| Q4 25 | $12.2B | $3.8B | ||
| Q3 25 | $12.1B | $3.4B | ||
| Q2 25 | $12.4B | $3.7B | ||
| Q1 25 | $12.4B | $3.8B | ||
| Q4 24 | $12.4B | $4.1B | ||
| Q3 24 | $12.8B | $3.7B | ||
| Q2 24 | $13.4B | $3.7B | ||
| Q1 24 | $13.4B | $4.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $182.0M | $61.0M |
| 自由现金流经营现金流 - 资本支出 | $161.8M | $43.0M |
| 自由现金流率自由现金流/营收 | 21.0% | 3.4% |
| 资本支出强度资本支出/营收 | 2.6% | 1.4% |
| 现金转化率经营现金流/净利润 | 1.85× | — |
| 过去12个月自由现金流最近4个季度 | $509.4M | $234.0M |
8季度趋势，按日历期对齐
经营现金流RVTYTNET
| Q4 25 | $182.0M | $61.0M | ||
| Q3 25 | $138.5M | $72.0M | ||
| Q2 25 | $134.3M | $75.0M | ||
| Q1 25 | $128.2M | $95.0M | ||
| Q4 24 | $174.2M | $65.0M | ||
| Q3 24 | $147.9M | $84.0M | ||
| Q2 24 | $158.6M | $39.0M | ||
| Q1 24 | $147.6M | $91.0M |
自由现金流RVTYTNET
| Q4 25 | $161.8M | $43.0M | ||
| Q3 25 | $120.0M | $55.0M | ||
| Q2 25 | $115.5M | $57.0M | ||
| Q1 25 | $112.2M | $79.0M | ||
| Q4 24 | $149.8M | $47.0M | ||
| Q3 24 | $125.6M | $59.0M | ||
| Q2 24 | $136.6M | $22.0M | ||
| Q1 24 | $129.7M | $73.0M |
自由现金流率RVTYTNET
| Q4 25 | 21.0% | 3.4% | ||
| Q3 25 | 17.2% | 4.5% | ||
| Q2 25 | 16.0% | 4.6% | ||
| Q1 25 | 16.9% | 6.1% | ||
| Q4 24 | 20.5% | 3.7% | ||
| Q3 24 | 18.4% | 4.8% | ||
| Q2 24 | 19.7% | 1.8% | ||
| Q1 24 | 20.0% | 5.8% |
资本支出强度RVTYTNET
| Q4 25 | 2.6% | 1.4% | ||
| Q3 25 | 2.6% | 1.4% | ||
| Q2 25 | 2.6% | 1.5% | ||
| Q1 25 | 2.4% | 1.2% | ||
| Q4 24 | 3.4% | 1.4% | ||
| Q3 24 | 3.3% | 2.0% | ||
| Q2 24 | 3.2% | 1.4% | ||
| Q1 24 | 2.7% | 1.4% |
现金转化率RVTYTNET
| Q4 25 | 1.85× | — | ||
| Q3 25 | 2.97× | 2.12× | ||
| Q2 25 | 2.49× | 2.03× | ||
| Q1 25 | 3.03× | 1.12× | ||
| Q4 24 | 1.84× | — | ||
| Q3 24 | 1.57× | 1.87× | ||
| Q2 24 | 2.87× | 0.65× | ||
| Q1 24 | 5.67× | 1.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
TNET
| Insurance Services | $1.1B | 85% |
| Professional Services | $169.0M | 14% |
